Sergey L. Stvolinsky

Sergey L. Stvolinsky

Auto-generated profile, based on publicly available information

Sergey L. Stvolinsky

Research Center of Neurology

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
OKOlga Kulikova
Olga Kulikova
DBDaniil Berezhnoy
Daniil Berezhnoy
SSSergey L. Stvolinsky
Sergey L. Stvolinsky
ALAlexander V Lopachev
Alexander V Lopachev
VOValentina S. Orlova
Valentina S. Orlova
TFTatiana Fedorova
Tatiana Fedorova

19 July 2023 in Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
DADenis Abaimov
Denis Abaimov
AKAnastasiya V. Khutorova
Anastasiya V. Khutorova
ASA. K. Sariev
A. K. Sariev
OKOlga Kulikova
Olga Kulikova
MBM. A. Belousova
M. A. Belousova
TFTatiana Fedorova
Tatiana Fedorova
The experimental study of the pharmacokinetic characteristics of a new pyrrole derivative of carnosine, pyrrolylcarnosine, was carried out. Based on the results of the experiment, the basic pharmacokinetic parameters of the drug are expected. The tissues and organs bioavailability was studied. The tropism of pyrrolylcarnosine to the organs of elimination and the ability of pyrrolylcarnosine to penetrate into the heart muscle tissue were shown.

18 September 2019 in Bulletin of Russian State Medical University
Verified
Journal Article
Open access
DBDaniil Berezhnoy
Daniil Berezhnoy
TFT.N. Fedorova
T.N. Fedorova
OKOlga Kulikova
Olga Kulikova
ASAlla V. Stavrovskaya
Alla V. Stavrovskaya
DADenis Abaimov
Denis Abaimov
SSS.L. Stvolinsky
S.L. Stvolinsky
The late stage of Parkinson’s disease is characterized by massive neuronal loss in the substantia nigra (SN) and degeneration of the dopaminergic innervation in the striatum. There is a need to assess the neuroprotective effect of antioxidants (AO) at this stage of the disease. The aim of our study was to assess the efficacy of two AO, carnosine and lipoic acid (LA), in the rat model of late-stage parkinsonism. The pathology was induced by a unilateral injection of 6-hydroxydopamine (6-OHDA) into the SN of the right brain hemisphere. AO were administered 4 times, starting on day 14 following the injection of the toxin. We investigated the effect of the injected drugs on the behavior of rats, the loss of neurons in the SN and the metabolism of biogenic neurotransmitter amines. Both AO dampened the development of 6-OHDA-induced neurological and behavioral symptoms. 6-OHDA induced a 90% drop (p = 0.01) in the levels of dopamine (DA) and its metabolites in the right striatum and caused death of over 95% of neurons (p = 0.01) in the SN of the right hemisphere (p = 0.01). AO did not have a significant effect on the number of neurons in the SN but caused an increase in the levels of DA metabolites, as compared to their levels in the animals exposed to 6-OHDA. Elevated DA (a 5.8-fold increase, p = 0.007) was observed only in the animals treated with carnosine. LA stimulated a 23% decline in serotonin levels (p = 0.06) and a 36% increase (p = 0.009) in its metabolite, 5-hydroxyindolacetic acid (5-HIAA). We conclude that although carnosine and LA did not have a direct neuroprotective effect, they could relieve the symptoms. This suggests that these AO could be used as an adjunctive component to antiparkinsonian therapy.